Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Rating of “Moderate Buy” by Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been given a consensus rating of “Moderate Buy” by the six research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $19.00.

Several research firms recently weighed in on ARTV. Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Artiva Biotherapeutics in a report on Friday, October 17th. HC Wainwright boosted their price target on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Thursday, October 30th. Wedbush increased their price objective on shares of Artiva Biotherapeutics from $18.00 to $23.00 and gave the company an “outperform” rating in a report on Friday, October 17th. Finally, Jefferies Financial Group raised Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th.

Artiva Biotherapeutics Stock Performance

Shares of Artiva Biotherapeutics stock opened at $4.86 on Friday. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $10.18. The firm’s 50-day simple moving average is $3.87 and its 200-day simple moving average is $3.24. The firm has a market cap of $119.31 million, a PE ratio of -1.88 and a beta of 2.92.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. On average, equities analysts predict that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Insiders Place Their Bets

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 25,500 shares of the company’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $6.00, for a total value of $153,000.00. Following the transaction, the chief executive officer owned 356,721 shares of the company’s stock, valued at approximately $2,140,326. This represents a 6.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 35,062 shares of company stock valued at $193,670. 21.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ground Swell Capital LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter worth about $38,000. Prelude Capital Management LLC acquired a new position in Artiva Biotherapeutics in the third quarter worth approximately $41,000. Bank of America Corp DE increased its holdings in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Artiva Biotherapeutics during the second quarter valued at approximately $48,000. Finally, Bridgeway Capital Management LLC acquired a new stake in Artiva Biotherapeutics in the second quarter valued at approximately $53,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.